Amgen Reports Positive Phase 2 Study of Olpasiran in Lipoprotein(a)
May 31 2022 - 9:59AM
Dow Jones News
By Colin Kellaher
Amgen Inc. on Tuesday reported positive topline data from a
Phase 2 study evaluating olpasiran in the reduction of
lipoprotein(a), reported to be an independent risk factor for
cardiovascular disease.
The Thousand Oaks, Calif., biotechnology company said the study
showed significant, sustained reduction in lipoprotein(a) in adults
with levels over 150 nmol/L and evidence of atherosclerotic
cardiovascular disease.
Olpasiran is designed to lower the body's production of
apolipoprotein(a), a key component of lipoprotein(a) that has been
associated with an increased risk of cardiovascular events.
Amgen said olpasiran showed a reduction from baseline in
lipoprotein(a) of up to or greater than 90% at week 36, the primary
endpoint, and week 48, the end of the treatment period, for the
majority of doses, adding that no new safety concerns were
identified.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 31, 2022 09:44 ET (13:44 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Sep 2023 to Sep 2024
